TiGenix gains CE mark for ChondroCelect, an ACI treatment for cartilage regeneration, plans launches in in Germany, the Netherlands, United Kingdom and Belgium

What differentiates ChondroCelect from other ACI treatments is that TiGenix tests the tissue sample taken from the patient for certain genetic markers that predict whether the cells are likely to regenerate “ChrodroCelect Receives First-of-Its-Kind EU Market Clearance” (HealthPointCapital)…  http://ow.ly/tGzr...